Riding the Digital Health Wave: The L.E.K. Digital Excellence Framework

In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations.

Biopharmaceutical executives have engaged in extensive debates about the need for and effectiveness of value-based contracts (VBCs) ever since the…

Providers are on high alert due to the global impact of COVID-19. Current and potential future waves of infections, lockdowns and reopenings — and their…

Skyrocketing medical costs, clinical variation and outcomes that underindex those of other developed nations have risen to the forefront as key issues…

This report highlights how biopharma executives should adapt to the evolving biopharma landscape in both the nearer and longer term.

The following materials provide a snapshot of the unprecedented scope and speed of biopharma’s therapeutics research and development (R&D) response to…

The presence of artificial intelligence (AI) in life sciences is growing quickly as a result of multiple AI companies focusing on drug discovery and…

Sej Brar describes what it takes to reshape and transform the strategic relevance of the medical affairs function. 

Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption

National Comprehensive Cancer Network (NCCN) recommendations are considered to be the gold standard for public and private insurers to use in making…

L.E.K. Consulting’s ninth annual Strategic Healthcare Review combines responses from hospital decision-makers with economic data and other insights.

This paper considers the market, competitive and regulatory dynamics driving homegrown innovation in healthcare in China, details the key “Made in China…